G1 Therapeutics, Inc. (GTHX) Bundle
A Brief History of G1 Therapeutics, Inc. (GTHX)
Founding and Early Development
G1 Therapeutics, Inc. was founded in 2008 and is based in Research Triangle Park, North Carolina. The company was established with a focus on developing innovative therapies for cancer patients.
Initial Public Offering (IPO)
On April 19, 2018, G1 Therapeutics went public, raising approximately $109 million by offering 6.3 million shares at a price of $17 per share. The IPO allowed the company to expand its research and development efforts significantly.
Clinical Trials and Product Pipeline
G1 Therapeutics’ lead product candidate is trilaciclib, which was developed to prevent chemotherapy-induced bone marrow suppression. The company initiated its first Phase 3 clinical trial in 2018. In 2020, results indicated that trilaciclib significantly reduced the incidence of chemotherapy-induced neutropenia (CIN) in patients with small cell lung cancer (SCLC).
| Year | Event | Clinical Trial Phase | Indication | Result Summary |
|---|---|---|---|---|
| 2018 | Phase 3 Trial Initiation | Phase 3 | Small Cell Lung Cancer | Successful in reducing CIN incidence |
| 2020 | FDA Submission | - | - | Submitted for accelerated approval |
| 2021 | FDA Approval | - | Small Cell Lung Cancer | Trilaciclib approved under accelerated pathway |
Financial Performance
For the fiscal year ended December 31, 2022, G1 Therapeutics reported total revenues of $14.2 million, primarily from the sales of trilaciclib and collaborations. The company had a net loss of $72.5 million in the same year, reflecting ongoing investments in research and development.
Collaborations and Partnerships
Throughout its history, G1 Therapeutics has entered several strategic partnerships. In 2021, the company entered a collaboration agreement with BG Medicine to combine trilaciclib with BG Medicine's diagnostic platform.
Recent Developments and Future Directions
As of September 2023, G1 Therapeutics is focused on expanding its clinical program for trilaciclib in multiple cancer settings. The company is also investigating additional indications through ongoing and upcoming clinical trials.
| Indication | Current Trials | Phase | Expected Completion |
|---|---|---|---|
| Breast Cancer | Trial 1 | Phase 2 | Q4 2023 |
| Colorectal Cancer | Trial 2 | Phase 1 | Q2 2024 |
| Head and Neck Cancer | Trial 3 | Phase 2 | Q1 2025 |
Stock Performance
As of October 2023, G1 Therapeutics shares are traded under the ticker GTHX. The stock has seen fluctuations, with a 52-week range of $3.50 to $15.00. The market capitalization is approximately $200 million.
A Who Owns G1 Therapeutics, Inc. (GTHX)
Current Shareholder Composition
The ownership of G1 Therapeutics, Inc. (GTHX) comprises various institutional and retail investors. As of the latest available data from the end of Q3 2023:
| Shareholder Type | Percentage Ownership | Number of Shares |
|---|---|---|
| Institutional Investors | 65.7% | 15,800,000 |
| Insiders | 10.5% | 2,400,000 |
| Retail Investors | 23.8% | 5,600,000 |
Major Institutional Shareholders
The following table lists the major institutional shareholders of G1 Therapeutics, Inc., along with their respective ownership percentages and share counts:
| Institution | Percentage Ownership | Number of Shares |
|---|---|---|
| Vanguard Group | 12.5% | 2,900,000 |
| BlackRock, Inc. | 10.0% | 2,200,000 |
| State Street Corporation | 8.3% | 1,900,000 |
| Wellington Management | 6.7% | 1,500,000 |
| Wells Fargo Advisors | 5.0% | 1,100,000 |
Insider Ownership
As of the end of Q3 2023, insider ownership consists of executive officers and board members. The following table summarizes the major insiders and their respective ownership:
| Name | Title | Percentage Ownership | Number of Shares |
|---|---|---|---|
| Jack Bailey | CEO | 3.1% | 700,000 |
| Sarah McDonald | CFO | 2.4% | 600,000 |
| Mark Johnson | Board Member | 1.5% | 300,000 |
| Linda Yang | Board Member | 1.0% | 200,000 |
Recent Stock Performance
G1 Therapeutics, Inc. (GTHX) has exhibited significant stock price movements in 2023. The following table represents the stock performance metrics:
| Metric | Value |
|---|---|
| Current Stock Price | $10.50 |
| Year-to-Date Return | 20.5% |
| Market Capitalization | $250 million |
| 52-Week High | $15.00 |
| 52-Week Low | $7.00 |
Conclusion on Ownership Structure
Understanding the ownership structure of G1 Therapeutics, Inc. reveals the significant influence of institutional investors, alongside notable insider participation. This framework provides a clearer view of the potential direction and governance of the company moving forward.
G1 Therapeutics, Inc. (GTHX) Mission Statement
Corporate Vision
The mission of G1 Therapeutics, Inc. is to develop innovative therapeutics for the treatment of cancer, focusing on improving patient outcomes and ensuring a better quality of life. The company is dedicated to addressing unmet medical needs through scientific excellence and collaboration.
Core Values
- Integrity: Committing to ethical practices in all interactions.
- Innovation: Fostering a culture of creativity to develop cutting-edge treatments.
- Collaboration: Working with patients, healthcare professionals, and researchers to advance medical science.
- Patient Focus: Prioritizing the needs and well-being of patients in every endeavor.
Strategic Objectives
G1 Therapeutics aims to achieve the following strategic objectives:
- Development Pipeline: Advance the pipeline with new drugs aimed at cancer therapy.
- Regulatory Success: Obtain regulatory approvals to bring therapies to market.
- Market Expansion: Increase market presence through strategic partnerships and collaborations.
Financial Overview
As of Q3 2023, G1 Therapeutics reported the following financial highlights:
| Financial Metric | Value |
|---|---|
| Revenue (Last Quarter) | $10 million |
| Net Loss (Last Quarter) | ($5 million) |
| Total Assets | $100 million |
| Market Capitalization | $300 million |
| Cash and Cash Equivalents | $50 million |
Research and Development Focus
G1 Therapeutics is concentrated on several key areas of research that highlight their commitment to innovative cancer treatment:
- G1T28: A novel oral therapy designed to enhance efficacy in combination with standard-of-care regimens.
- G1T34: Targeting specific cancer pathways to improve patient outcomes.
- Clinical Trials: Ongoing studies conducted in partnership with leading oncology research institutions.
Current Partnerships
The company has established various collaborations aimed at enhancing its research capabilities:
| Partner | Focus Area | Year Established |
|---|---|---|
| University of North Carolina | Oncology Research | 2021 |
| Johns Hopkins University | Clinical Trials | 2020 |
| Amgen | Therapeutic Development | 2022 |
Commitment to Patients
G1 Therapeutics is dedicated to improving patient lives through transformative therapies and ongoing support:
- Patient Advocacy: Engaging with patient advocacy groups to better understand needs.
- Access Programs: Implementing access programs that ensure availability of therapies.
- Education Initiatives: Providing resources and information to empower patients.
Conclusion
G1 Therapeutics is focused on fulfilling its mission to innovate cancer treatments, underscored by a strong commitment to ethical practices, scientific innovation, and collaboration with stakeholders in the healthcare community.
How G1 Therapeutics, Inc. (GTHX) Works
Company Overview
G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Durham, North Carolina. The company focuses on developing innovative therapeutics for the treatment of cancer. G1 Therapeutics was founded in 2008 and has established a portfolio of drug candidates aimed at addressing unmet medical needs.
Pipeline and Product Development
The company's lead product candidate is bempeg (formerly G1T38), an immune-oncology agent aiming to enhance the body's immune response against tumors. Bempeg is currently being evaluated in combination with pembrolizumab for patients with certain types of cancers, including metastatic melanoma and non-small cell lung cancer.
| Product Candidate | Type | Indication | Phase | Expected Milestone |
|---|---|---|---|---|
| Bempeg | Immune-Oncology | Metastatic Melanoma | Phase 3 | FDA submission in 2024 |
| G1T48 | Oral Selective Estrogen Receptor Modulator | Breast Cancer | Phase 2 | Data readout expected in 2024 |
Financial Performance
As of the second quarter of 2023, G1 Therapeutics reported cash and cash equivalents amounting to $136.3 million. The company has been actively managing its financial resources to support the ongoing clinical trials and operations.
| Financial Metric | Q2 2023 Amount | Q1 2023 Amount | Change (%) |
|---|---|---|---|
| Cash and Cash Equivalents | $136.3 million | $156.0 million | -12.1% |
| Net Loss | $20.6 million | $18.5 million | +11.4% |
Stock Performance and Market Capitalization
G1 Therapeutics is publicly traded on the NASDAQ under the ticker symbol GTHX. As of October 20, 2023, the market capitalization of G1 Therapeutics stands at approximately $280.0 million.
| Date | Stock Price ($) | Market Cap ($ million) |
|---|---|---|
| October 20, 2023 | $4.50 | $280.0 |
| July 21, 2023 | $6.77 | $430.0 |
Collaborations and Partnerships
G1 Therapeutics has engaged in several collaborations to enhance its research and development capabilities. Notable collaborations include those with large pharmaceutical firms for both drug development and commercialization.
- Collaboration with Merck for bempeg
- Partnership with other biotech firms for combination therapy studies
- Academic partnerships for pre-clinical research support
Regulatory and Clinical Trials
The company is subject to oversight by the U.S. Food and Drug Administration (FDA) as well as other regulatory bodies in different jurisdictions. Clinical trials are conducted in adherence to Good Clinical Practice (GCP) guidelines.
Competitive Landscape
G1 Therapeutics operates in a competitive environment with numerous companies developing similar cancer therapies. Some key competitors include:
- Checkmate Pharmaceuticals
- Arcus Biosciences
- Bristol-Myers Squibb
How G1 Therapeutics, Inc. (GTHX) Makes Money
Revenue Generation from Product Sales
G1 Therapeutics, Inc. generates revenue primarily through the sale of its therapeutic products. As of the third quarter of 2023, the company reported product revenue of $2.5 million from the sale of its lead product, Cosela, which is indicated for use in patients receiving chemotherapy.
Partnerships and Collaborations
The company engages in strategic collaborations with other pharmaceutical companies to enhance its market reach and product development pipeline. In 2022, G1 entered a collaboration with AbbVie to co-develop novel drug candidates, which is expected to provide milestone payments and royalties.
- Collaboration agreement with AbbVie includes potential milestone payments of up to $250 million.
- Royalty rates are expected to range between 8% to 12% on net sales.
Research and Development Grants
G1 Therapeutics also benefits from government and private research grants to fund its clinical trials and drug development. In 2023, the company secured a grant from the National Institutes of Health (NIH) worth $3 million to support its research on cancer therapies.
Financial Performance Overview
| Year | Total Revenue | Net Income (Loss) | R&D Expenses | SG&A Expenses |
|---|---|---|---|---|
| 2021 | $1.2 million | ($30.4 million) | $25.2 million | $5 million |
| 2022 | $3.1 million | ($35.5 million) | $28 million | $7.5 million |
| 2023 (Q3) | $2.5 million | ($20 million) | $15 million | $5.5 million |
Intellectual Property Management
Intellectual property rights play a crucial role in G1’s revenue strategy. The company holds multiple patents, facilitating a competitive advantage in the market. In 2023, the company was granted several key patents that may lead to increased licensing opportunities in the oncology space.
Future Growth and Market Expansion
G1 Therapeutics is focusing on expanding its product pipeline, particularly in oncology. The anticipated launch of additional therapies is projected to drive revenue growth substantially. Analysts estimate that successful commercialization of new products could potentially increase revenue to over $100 million by 2025.
G1 Therapeutics, Inc. (GTHX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support